Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth

Nature Medicine

Volumn 9, Issue 8, 2003, Pages 1026-1032

  Fahmy, Roger G ^a,b   Dass, Crispin R ^c   Sun, Lun Quan ^c   Chesterman, Colin N ^a,b   Khachigian, Levon M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c Johnson and Johnson Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; ENZYME; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; MATRIGEL; MESSENGER RNA; RNA CLEAVING PHOSPHODIESTER LINKED DNA BASED ENZYME; TRANSCRIPTION FACTOR EGR 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

5' UNTRANSLATED REGION; ADOLESCENT; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD CLOTTING; BODY WEIGHT; BREAST CARCINOMA; CANCER INHIBITION; CELL DIVISION; CELL MIGRATION; CONTROLLED STUDY; CORNEA VASCULARIZATION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROTUBULE; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA DEGRADATION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; WOUND HEALING;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL MOVEMENT; DNA, CATALYTIC; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICROTUBULES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MUS MUSCULUS;

EID: 0041464740     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm905     Document Type: Article

References (45)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
2. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175,409-416 (1972).
3. Kerbel, R, & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739 (2002).
4. Sukhatme, V.P. et al. A zinc-finger encoding gene corregulated with c-Fos during growth and differentiation and after depolarization. Cell 53, 37-43 (1988).
5. Gashler, A. & Sukhatme, V. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog, Nucl. Acid Res, 50, 191-224 (1995).
6. Khachigian, L.M., Lindner, V., Williams, A.J. & Collins, T. Egr-1-induced endothelial gene expression: a common theme in vascular injury, Science 271, 1427-1431 (1996).
7. Khachigian, L.M. & Collins, T. Inducible expression of Egr-1-dependent genes: a paradigm of transcriptional activation in vascular endothelium. Circ. Res, 81, 457-461 (1997).
8. Santoro, S.W. & Joyce, G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA 94, 4262-4266 (1997).
9. Montesano, R., Orci, L. & Vassalli, P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J, Cell Biol. 97, 1648-1652 (1983).
10. Cieslak, M. et al. DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and Matrigel, J. Biol. Chem. 277, 6779-6787 (2002).
11. Lee, S. et al. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 273, 1219-1221 (1996).
12. Fournier, G.A., Lutty, G.A., Watt, S., Fenselau, A. & Patz, A, A corneal micropocket assay for angiogenesis in the rat eye. Invest. Ophthalmol. Vis. Sci. 21, 351-354 (1981).
13. Parry, T.J. et al. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res. 27, 2569-2577 (1999).
14. Lowe, H.C, et al. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ. Res. 89, 670-677 (2001).
15. Shing, Y. et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor, Science 223, 1296-1298 (1984).
16. Santiago, F.S., Lowe, H.C., Day, F.L., Chesterman, C,N. & Khachigian, L.M. Egr-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am. J. Pathol. 154, 937-944 (1999).
17. Wang, D., Mayo, M.W. & Baldwin, A.S., Jr. Basic fibroblast growth factor transcriptional autoregulation requires EGR-1. Oncogene 14, 2291-2299 (1997).
18. Biesiada, E., Razandi, M. & Levin, E.R. Egr-1 activates basic fibroblast growth factor transcription. J. Biol. Chem. 271, 18576-18581 (1996).
19. McLeskey, S.W, et al. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am. J. Pathol. 153, 1993-2006 (1998).
20. McLeskey, S.W. et al. Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res. Treat. 39, 103-117 (1996).
21. Zhang, L., Kharbanda, S., McLeskey, S.W. & Kern, F.G. Overexpression of fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes. Cancer Res, 59, 5023-5029 (1999).
22. McLeskey, S.W. et al. Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br. J. Cancer 73, 1053-1062 (1996).
23. Zhang, L., Kharabanda, S., Hanfelt, J. & Kern, F.G. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res. 58, 352-361 (1998).
24. Karpanen, T. et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61, 1786-1790 (2001).
25. Gille, J., Swerlick, R.A. & Caughman, S.W. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. 16, 750-759 (1997).
26. Finkenzeller, G., Sparacio, A., Technau, A., Marme, D. & Siemeister, G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15, 669-676 (1997).
27. Li, Y. et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195, 1575-1584 (2002).
28. Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209-5218 (1999).
29. Shiose, S. et al. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest. Opthalmol. Vis. Sci. 41, 2395-2403 (2000).
30. Dennis, P.A. & Rifkin, D.B. Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. J Cell. Physiol. 144, 84-98 (1990).
31. Ogawa, T., Takayama, K., Takakura, N., Kitano, S. & Ueno, H. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther. 9, 633-640 (2002).
32. Wedge, S.R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655 (2002).
33. Battegay, E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 73, 333-346 (1995).
34. Haas, T.L., Stitelman, D., Davis, S.J., Apte, S.S. & Madri, J.A. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase. J. Biol. Chem. 274, 22679-22685 (1999).
35. Goldberg, E.P., Hadba, A.R., Almond, B.A. & Marotta, J.S. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J. Pharm. Pharmacol. 54, 159-180 (2002).
36. Usman, N. & Blatt, L.M. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106, 1197-1202 (2000).
37. Pavco, P.A. et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. 6, 2094-2103 (2000).
38. Masood, R. et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98, 1904-1913 (2001).
39. Herold-Mende, C. et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab. Invest. 79, 1573-1782 (1999).
40. Eyetech. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22, 143-152 (2002).
41. Khachigian, L.M. DNAzymes: cutting a path to a new class of therapeutics. Curr. Opin. Mol. Ther. 4, 119-121 (2002).
42. Santiago, F.S. et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth factor injury. Nat. Med. 11, 1264-1269 (1999).
43. Khachigian, L.M., Fahmy, R.G., Zhang, G., Bobryshev, Y.V. & Kaniaros, A. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury: inhibition by a novel DNAzyme targeting c-Jun. J. Biol. Chem. 277, 22985-22991 (2002).
44. Chan, J.C., Duszczyszyn, D.A., Castellino, F.J. & Ploplis, V.A. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am. J. Pathol. 159, 1681-1688 (2001).
45. Visvanathan, S., Geczy, C.L., Harmer, J.A. & McNeil, H.P. Monocyte tissue factor induction by activation of beta 2-glycoprotein-1-specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies. J. Immunol. 165, 2258-2262 (2000).